•  
  •  
 

Abstract

Objectives:

To assess the antidiabetic potential of

Shilajatvadi Lauha

(SL) processed with

Daruharidra

(modified SL [MSL]) in streptozotocin (STZ)-nicotinamide (NA)-induced diabetic rats.

Materials and Methods:

Animals were divided into diabetic and nondiabetic groups. Type 2 diabetes in rats was induced with a single dose of STZ (65 mg/kg) NA (110 mg/kg) intraperitoneal diabetic rats were treated with formulation MSL (10, 30, and 100 mg/kg) and glibenclamide (10 mg/kg) once daily for 14 days orally. After 14 days treatment, fasting blood glucose and plasma insulin were assayed. Different biochemical parameters such as total cholesterol (TC), triglycerides (TGs), low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), and very LDL-C (VLDL-C) were also examined.

Results:

MSL significantly lowered the blood glucose and increases insulin level, which was comparable to the standard antidiabetic drug, glibenclamide. Treatment with MSL showed a significantly reduction in the levels of TC, TG, LDL-C, and VLDL-C and increases the level of HDL-C.

Conclusion:

MSL possess significant antidiabetic and antihyperlipidemic activity in Type 2 diabetes mellitus rats. The results are encouraging and further studies can be used to evaluate the exact mechanism of action to develop a novel molecule that will benefit the ailing.

Pages

308

Last Page

314

Share

COinS